Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE
Brief Summary:
This is a prospective, randomized, double blind, placebo-controlled clinical trial.
The study will take place at 4 sites.
This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48.
AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ? 200 and/or have personal and/or familial history of atopy.
Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).